Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPM1 | P06748 | 2/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | GLP1R | P43220 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30040923 | 1.00 | NPM1 (0.44) | NPM1ALKPDE2APDE10APDE4B | |
| SCHEMBL1537620 | 0.81 | RAB9A (0.44) | SMN1; SMN2HTTRAB9ALMNACYP11B1 | |
| SCHEMBL12853410 | 0.81 | FABP4 (0.48) | NPM1ALKPDE2APDE10AFABP4 | |
| SCHEMBL14247220 | 0.81 | DHFR (0.41) | NPM1ALKFABP4SMN1; SMN2HTT | |
| SCHEMBL29827557 | 0.81 | FABP4 (0.48) | NPM1ALKPDE2APDE10AFABP4 | |
| SCHEMBL1537646 | 0.80 | CYP11B1 (0.53) | PDE2APDE10ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL20987182 | 0.78 | MAPT (0.42) | NPM1ALKPDE2APDE10AFABP4 | |
| SCHEMBL20987163 | 0.78 | FABP4 (0.42) | NPM1ALKPDE2APDE10APDE4B | |
| SCHEMBL29729386 | 0.78 | MAPT (0.42) | NPM1ALKPDE2APDE10AFABP4 | |
| SCHEMBL17674019 | 0.77 | SMN1; SMN2 (0.58) | NPM1ALKPDE2APDE10ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3492462-B1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-113382991-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-12-27 | — | — | CN | disclosed |
| CN-113382991-A | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-09-07 | — | — | US | disclosed |
| CN-110818690-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-110818690-A | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-108602802-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-3492462-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | Shenzhen Targetrx, Inc. (CN) | 2019-06-05 | — | — | EP | disclosed |
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | LCK, WEE1, JAK1 | NPM1 501/4885ALK 291/4885PDE2A 2377/4885 |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | LCK, WEE1, JAK1 | NPM1 501/4885ALK 291/4885PDE2A 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.